Background: The act of intravenous misuse is common in patients under opioid maintenance treatment (OMT), but information on associated factors is still limited. Objectives: To explore factors associated with (a) intravenous OMT misuse, (b) repeated misuse, (c) emergency room (ER) admission, (d) misuse of different OMT types and (e) concurrent benzodiazepine misuse. Methods: We recruited 3,620 patients in 27 addiction units in Italy and collected data on the self-reported rate of intravenous injection of methadone (MET), buprenorphine (BUP), BUP-naloxone (NLX), OMT dosage and type, experience of and reason for misuse, concurrent intravenous benzodiazepine misuse, pattern of -misuse in relation to admission to the addiction unit and ER -admissions because of misuse. According to inclusion/exclusion criteria, 2,585 patients were included. Results: Intravenous misuse of OMT substances was found in 28% of patients with no difference between OMT types and was associated with gender, age, type of previous opioid abuse and intravenous benzodiazepine misuse. Repeated OMT misuse was reported by 20% (i.e., 71% of misusers) of patients and was associated with positive OMT misuse experience and intravenous benzodiazepine misuse. Admission to the ER because of misuse complications was reported by 34% of patients, this outcome being associated with gender, employment, type of previous opioid abuse and intravenous benzodiazepine misuse. OMT dosage was lower than the recommended maintenance dosage. Conclusions: We offered new information on factors associated with intravenous OMT misuse, repeated misuse and ER admission in Italian patients under OMT. Our data indicate that BUP-NLX misuse is not different from that of BUP or MET. Choosing the more expensive BUP-NLX over MET will likely not lead to the expected reduction of the risk of injection misuse of the OMT. Instead of prescribing new and expensive OMT formulations, addiction unit physicians and medical personnel should better focus on patient’s features that are associated with a higher likelihood of misuse. Care should be paid to concurrent benzodiazepine and OMT misuse.

Keywords:
Benzodiazepine, Buprenorphine, Compliance, Concurrent use, Misuse, Methadone, Mu agonist, Naloxone, Opioid, Opioid maintenance treatment
1.
Humeniuk R, Ali R, McGregor C, Darke S: Prevalence and correlates of intravenous methadone syrup administration in Adelaide, Australia. Addiction 2003; 98: 413–418.
2.
Nordmann S, Frauger E, Pauly V, Orléans V, Pradel V, Mallaret M, et al: Misuse of buprenorphine maintenance treatment since introduction of its generic forms: OPPIDUM survey. Pharmacoepidemiol Drug Saf 2012; 21: 184–190.
3.
Mattick RP, Breen C, Kimber J, Davoli M: Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2014:CD002207.
4.
Bell J: Pharmacological maintenance treatments of opiate addiction. Br J Clin Pharmacol 2014; 77: 253–263.
5.
Casati A, Sedefov R, Pfeiffer-Gerschel T: Misuse of medicines in the European Union: a systematic review of the literature. Eur Addict Res 2012; 18: 228–245.
6.
Dale O, Hoffer C, Sheffels P, Kharasch ED: Disposition of nasal, intravenous, and oral methadone in healthy volunteers. Clin Pharmacol Ther 2002; 72: 536–545.
7.
Robinson GM, Kemp R, Lee C, Cranston D: Patients in methadone maintenance treatment who inject methadone syrup: a preliminary study. Drug Alcohol Rev 2000; 19: 447–450.
8.
Darke S: Self-report among injecting drug users: a review. Drug Alcohol Depend 1998; 51: 253–263.
9.
Chevalley AE, Besson J, Croquette-Krokar M, Davidson C, Dubois JA, Uehlinger C, et al: Prevalence of methadone injection in three Swiss cities. Presse Med 2005; 34: 776–780.
10.
Rosenblum A, Parrino M, Schnoll SH, Fong C, Maxwell C, Cleland CM, et al: Prescription opioid abuse among enrollees into methadone maintenance treatment. Drug Alcohol Depend 2007; 90: 64–71.
11.
Roux P, Villes V, Bry D, Spire B, Feroni I, Marcellin F, et al: Buprenorphine sniffing as a response to inadequate care in substituted patients: results from the Subazur survey in south-eastern France. Addict Behav 2008; 33: 1625–1629.
12.
Winstock AR, Lea T, Sheridan J: Prevalence of diversion and injection of methadone and buprenorphine among clients receiving opioid treatment at community pharmacies in New South Wales, Australia. Int J Drug Policy 2008; 19: 450–458.
13.
Maremmani I, Pacini M, Pani PP, Popovic D, Romano A, Maremmani AG, et al: Use of street methadone in Italian heroin addicts presenting for opioid agonist treatment. J Addict Dis 2009; 28: 382–388.
14.
Judson G, Bird R, O’Connor P, Bevin T, Loan R, Schroder M, et al: Drug injecting in patients in New Zealand methadone maintenance treatment programs: an anonymous survey. Drug Alcohol Rev 2010; 29: 41–46.
15.
Bouquié R, Wainstein L, Pilet P, Mussini JM, Deslandes G, Clouet J, et al: Crushed and injected buprenorphine tablets: characteristics of princeps and generic solutions. PLoS One 2014; 9:e113991.
16.
Quaglio G, Talamini G, Lechi A, Venturini L, Lugoboni F, Mezzelani P; et al: Study of 2708 heroin-related deaths in north-eastern Italy 1985–98 to establish the main causes of death. Addiction 2001; 96: 1127–1137.
17.
Weimer MB, Korthuis PT, Behonick GS, Wunsch MJ: The source of methadone in overdose deaths in Western Virginia in 2004. J Addict Med 2011; 5: 188–202.
18.
Moratti E, Kashanpour H, Lombardelli T, Maisto M: Intravenous misuse of buprenorphine: characteristics and extent among -patients undergoing drug maintenance -therapy. Clin Drug Investig 2010; 30(suppl 1): 3–11.
19.
Cicero TJ, Ellis MS, Surratt HL, Kurtz SP: Factors contributing to the rise of buprenorphine misuse: 2008–2013. Drug Alcohol Depend 2014; 142: 98–104.
20.
Comer SD, Sullivan MA, Vosburg SK, Manubay J, Amass L, Cooper ZD, et al: Abuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in buprenorphine-maintained intravenous heroin abusers. Addiction 2010; 105: 709–718.
21.
Soyka M: New developments in the management of opioid dependence: focus on sublingual buprenorphine-naloxone. Subst Abuse Rehabil 2015; 6: 1–14.
22.
Bruce RD, Govindasamy S, Sylla L, Kamarulzaman A, Altice F: Lack of reduction in buprenorphine injection after introduction of co-formulated buprenorphine/naloxone to the Malaysian market. Am J Drug Alcohol Abuse 2009; 35: 68–72.
23.
Larance B, Lintzeris N, Ali R, Dietze P, Mattick R, Jenkinson R, et al: The diversion and injection of a buprenorphine-naloxone soluble film formulation. Drug Alcohol Depend 2014; 136: 21–27.
24.
Chen KW, Berger CC, Forde DP, D’Adamo C, Weintraub E, Gandhi D: Benzodiazepine use and misuse among patients in a methadone program. BMC Psychiatry 2011; 11: 90.
25.
Pauly V, Pradel V, Pourcel L, Nordmann S, Frauger E, Lapeyre-Mestre M, et al: Estimated magnitude of diversion and abuse of opioids relative to benzodiazepines in France. Drug Alcohol Depend 2012; 126: 13–20.
26.
Herbert A, Gilbert R, Cottrell D, Li L: Causes of death up to 10 years after admissions to hospitals for self-inflicted, drug-related or alcohol-related, or violent injury during adolescence: a retrospective, nationwide, cohort study. Lancet 2017; 390: 577–587.
27.
Sun EC, Dixit A, Humphreys K, Darnall BD, Baker LC, Mackey S: Association between concurrent use of prescription opioids and benzodiazepines and overdose: retrospective analysis. BMJ 2017; 356:j760.
28.
Vicknasingam B, Mazlan M, Schottenfeld RS, Chawarski MC: Injection of buprenorphine and buprenorphine/naloxone tablets in Malaysia. Drug Alcohol Depend 2010; 111: 44–49.
29.
Nielsen S, Degenhardt L, Hoban B, Gisev N: Comparing Opioids: A Guide to Estimating Oral Morphine Equivalents (OME) in Research. Technical Report No. 329. Sydney, National Drug and Alcohol Research Centre, University of New South Wales, 2014.
30.
Lugoboni F, Zamboni L, Federico A, Tamburin S; Gruppo InterSERT di Collaborazione Scientifica (GICS): Erectile dysfunction and quality of life in men receiving methadone or buprenorphine maintenance treatment. A cross-sectional multicentre study. PLoS One 2017; 12:e0188994.
31.
Launonen E, Wallace I, Kotovirta E, Alho H, Simojoki K: Factors associated with non-adherence and misuse of opioid maintenance treatment medications and intoxicating drugs among Finnish maintenance treatment patients. Drug Alcohol Depend 2016; 162: 227–235.
32.
Hosmer DW, Lemeshow S: Applied Logistic Regression (ed 2). New York, Wiley, 2000.
33.
Duffy P, Baldwin H: The nature of methadone diversion in England: a Merseyside case study. Harm Reduct J 2012; 9: 3.
34.
Vidal-Trecan G, Varescon I, Nabet N, Boissonnas A: Intravenous use of prescribed sublingual buprenorphine tablets by drug users receiving maintenance therapy in France. Drug Alcohol Depend 2003; 69: 175–181.
35.
West NA, Severtson SG, Green JL, Dart RC: Trends in abuse and misuse of prescription opioids among older adults. Drug Alcohol Depend 2015; 149: 117–121.
36.
Krause D, Plörer D, Koller G, Martin G, Winter C, Adam R, et al: High concomitant misuse of fentanyl in subjects on opioid maintenance treatment. Subst Use Misuse 2017; 52: 639–645.
37.
Comer SD, Collins ED: Self-administration of intravenous buprenorphine and the buprenorphine/naloxone combination by recently detoxified heroin abusers. J Pharmacol Exp Ther 2002; 303: 695–703.
38.
Walsh SL, Nuzzo PA, Babalonis S, Casselton V, Lofwall MR: Intranasal buprenorphine alone and in combination with naloxone: abuse liability and reinforcing efficacy in physically dependent opioid abusers. Drug Alcohol Depend 2016; 162: 190–198.
39.
Guichard A, Lert F, Calderon C, Gaigi H, Maguet O, Soletti J, et al: Illicit drug use and injection practices among drug users on methadone and buprenorphine maintenance treatment in France. Addiction 2003; 98: 1585–1597.
40.
Jones CM: Trends and key correlates of prescription opioid injection misuse in the United States. Addict Behav 2018; 78: 145–152.
41.
Bouvier BA, Waye KM, Elston B, Hadland SE, Green TC, Marshall BDL: Prevalence and correlates of benzodiazepine use and misuse among young adults who use prescription opioids non-medically. Drug Alcohol Depend 2018; 183: 73–77.
42.
NICE: Methadone and buprenorphine for the management of opioid dependence. https://www.nice.org.uk/guidance/TA114/chapter/1-Guidance (accessed on November 4, 2018).
43.
Degenhardt L, Larance BK, Bell JR, Winstock AR, Lintzeris N, Ali RL, et al: Injection of medications used in opioid substitution treatment in Australia after the introduction of a mixed partial agonist-antagonist formulation. Med J Aust 2009; 131: 161–165.
44.
Darke S, Topp L, Ross J: The injection of methadone and benzodiazepines among Sydney injecting drug users 1996–2000: 5-year monitoring of trends from the illicit drug reporting system. Drug Alcohol Rev 2002; 21: 27–32.
© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.